The purpose of this study is to evaluate the utility of claims data as a data source to evaluate quality of care in new onset rheumatoid arthritis; to measure the quality of care for patients with new onset rheumatoid arthritis with regard to arthritis co-morbid conditions and health care maintenance, and to identify factors associated with better attainment of quality standards. This study will prospectively follow a cohort of 400 patients with new onset rheumatoid arthritis for two years through patient surveys and claims data. Subjects will be enrolled through one large managed care organization (MCO) located in Southern California which represents an average of 2.8 million covered lives per year. Using a claims based algorithm, the 1998 through 1999 claims data for this MCO will be screened for incident cases of rheumatoid arthritis. Patients between ages 18 and 62 will be eligible for enrollment. A screening survey which will ascertain 1) whether a patient has been diagnosed with rheumatoid arthritis and/or 2) if the patient meets the 1987 American Rheumatism Association (ARA) criteria for rheumatoid arthritis by self report will be sent by mail to all eligible patients to invite participation. The first 400 responding patients who have had a prior diagnosis or meet the ARA criteria will be enrolled. Patients will complete telephone surveys which assess health status every six during the study. By using data elements from claims data, patient self report. and medical records, the structure, process, outcomes and quality of care will be assessed. Items measured in the claims data will be validated through the patient self report and medical record review. This study will inform us regarding the predictive value of claims data for identifying patients with rheumatoid arthritis and describing utilization. It will also describe the utility of claims data for assessing the process and quality of care for rheumatoid arthritis.

Project Start
1998-09-15
Project End
1999-06-30
Budget Start
Budget End
Support Year
11
Fiscal Year
1998
Total Cost
Indirect Cost
Name
University of California Los Angeles
Department
Type
DUNS #
119132785
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Jawaheer, Damini; Maranian, Paul; Park, Grace et al. (2010) Disease progression and treatment responses in a prospective DMARD-naive seropositive early rheumatoid arthritis cohort: does gender matter? J Rheumatol 37:2475-85
Ranganath, Veena K; Yoon, Jeonglim; Khanna, Dinesh et al. (2007) Comparison of composite measures of disease activity in an early seropositive rheumatoid arthritis cohort. Ann Rheum Dis 66:1633-40
Kahn, Katherine L; MacLean, Catherine H; Liu, Honghu et al. (2007) The complexity of care for patients with rheumatoid arthritis: metrics for better understanding chronic disease care. Med Care 45:55-65
Kahn, K L; Maclean, C H; Wong, A L et al. (2007) Assessment of American College of Rheumatology quality criteria for rheumatoid arthritis in a pre-quality criteria patient cohort. Arthritis Rheum 57:707-15
Kahn, K L; MacLean, C H; Liu, H et al. (2006) Application of explicit process of care measurement to rheumatoid arthritis: Moving from evidence to practice. Arthritis Rheum 55:884-91
Paulus, Harold E; Oh, MyungShin; Sharp, John T et al. (2004) Classifying structural joint damage in rheumatoid arthritis as progressive or nonprogressive using a composite definition of joint radiographic change: a preliminary proposal. Arthritis Rheum 50:1083-96
Liu, Honghu; Harker, Judith O; Wong, Andrew L et al. (2004) Case finding for population-based studies of rheumatoid arthritis: comparison of patient self-reported ACR criteria-based algorithms to physician-implicit review for diagnosis of rheumatoid arthritis. Semin Arthritis Rheum 33:302-10
Riemekasten, Gabriela; Langnickel, Dirk; Enghard, Philipp et al. (2004) Intravenous injection of a D1 protein of the Smith proteins postpones murine lupus and induces type 1 regulatory T cells. J Immunol 173:5835-42
La Cava, Antonio; Ebling, Fanny M; Hahn, Bevra H (2004) Ig-reactive CD4+CD25+ T cells from tolerized (New Zealand Black x New Zealand White)F1 mice suppress in vitro production of antibodies to DNA. J Immunol 173:3542-8
Amjadi-Begvand, Sogol; Khanna, Dinesh; Park, Grace S et al. (2004) Dating the ""window of therapeutic opportunity"" in early rheumatoid arthritis: accuracy of patient recall of arthritis symptom onset. J Rheumatol 31:1686-92

Showing the most recent 10 out of 111 publications